470 related articles for article (PubMed ID: 9177242)
1. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy.
Koschinsky T; He CJ; Mitsuhashi T; Bucala R; Liu C; Buenting C; Heitmann K; Vlassara H
Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6474-9. PubMed ID: 9177242
[TBL] [Abstract][Full Text] [Related]
2. Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration.
He C; Sabol J; Mitsuhashi T; Vlassara H
Diabetes; 1999 Jun; 48(6):1308-15. PubMed ID: 10342821
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycosylation end products in patients with diabetic nephropathy.
Makita Z; Radoff S; Rayfield EJ; Yang Z; Skolnik E; Delaney V; Friedman EA; Cerami A; Vlassara H
N Engl J Med; 1991 Sep; 325(12):836-42. PubMed ID: 1875967
[TBL] [Abstract][Full Text] [Related]
4. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients.
Uribarri J; Peppa M; Cai W; Goldberg T; Lu M; He C; Vlassara H
J Am Soc Nephrol; 2003 Mar; 14(3):728-31. PubMed ID: 12595509
[TBL] [Abstract][Full Text] [Related]
5. Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria.
Turk N; Mornar A; Mrzljak V; Turk Z
Diabetes Metab; 2004 Apr; 30(2):187-92. PubMed ID: 15223992
[TBL] [Abstract][Full Text] [Related]
6. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients.
Uribarri J; Peppa M; Cai W; Goldberg T; Lu M; Baliga S; Vassalotti JA; Vlassara H
Am J Kidney Dis; 2003 Sep; 42(3):532-8. PubMed ID: 12955681
[TBL] [Abstract][Full Text] [Related]
7. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
8. Atherogenic lipoprotein changes in diabetic nephropathy.
Shoji T; Emoto M; Kawagishi T; Kimoto E; Yamada A; Tabata T; Ishimura E; Inaba M; Okuno Y; Nishizawa Y
Atherosclerosis; 2001 Jun; 156(2):425-33. PubMed ID: 11395040
[TBL] [Abstract][Full Text] [Related]
9. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes.
Beisswenger PJ; Makita Z; Curphey TJ; Moore LL; Jean S; Brinck-Johnsen T; Bucala R; Vlassara H
Diabetes; 1995 Jul; 44(7):824-9. PubMed ID: 7789650
[TBL] [Abstract][Full Text] [Related]
10. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients.
Yanagisawa K; Makita Z; Shiroshita K; Ueda T; Fusegawa T; Kuwajima S; Takeuchi M; Koike T
Metabolism; 1998 Nov; 47(11):1348-53. PubMed ID: 9826211
[TBL] [Abstract][Full Text] [Related]
11. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products.
Zheng F; He C; Cai W; Hattori M; Steffes M; Vlassara H
Diabetes Metab Res Rev; 2002; 18(3):224-37. PubMed ID: 12112941
[TBL] [Abstract][Full Text] [Related]
12. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure.
Makita Z; Bucala R; Rayfield EJ; Friedman EA; Kaufman AM; Korbet SM; Barth RH; Winston JA; Fuh H; Manogue KR
Lancet; 1994 Jun; 343(8912):1519-22. PubMed ID: 7911868
[TBL] [Abstract][Full Text] [Related]
13. Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse age-mediated cellular effects in vitro: a potential AGE sequestration therapy for diabetic nephropathy?
Zheng F; Cai W; Mitsuhashi T; Vlassara H
Mol Med; 2001 Nov; 7(11):737-47. PubMed ID: 11788787
[TBL] [Abstract][Full Text] [Related]
14. Serum type IV collagen in diabetic patients at risk for nephropathy.
Cohen MP; Shearman CW; Lautenslager GT
Diabetes Care; 2001 Aug; 24(8):1324-7. PubMed ID: 11473064
[TBL] [Abstract][Full Text] [Related]
15. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
Tan SMQ; Chiew Y; Ahmad B; Kadir KA
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of low molecular weight advanced glycation end products in diabetic subjects.
Sharp PS; Rainbow S; Mukherjee S
Diabet Med; 2003 Jul; 20(7):575-9. PubMed ID: 12823240
[TBL] [Abstract][Full Text] [Related]
17. RAGE mRNA expression in the diabetic mouse kidney.
Ziyadeh FN; Cohen MP; Guo J; Jin Y
Mol Cell Biochem; 1997 May; 170(1-2):147-52. PubMed ID: 9144329
[TBL] [Abstract][Full Text] [Related]
18. Dietary flaxseed meal reduces proteinuria and ameliorates nephropathy in an animal model of type II diabetes mellitus.
Velasquez MT; Bhathena SJ; Ranich T; Schwartz AM; Kardon DE; Ali AA; Haudenschild CC; Hansen CT
Kidney Int; 2003 Dec; 64(6):2100-7. PubMed ID: 14633132
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy.
Vlassara H; Cai W; Crandall J; Goldberg T; Oberstein R; Dardaine V; Peppa M; Rayfield EJ
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15596-601. PubMed ID: 12429856
[TBL] [Abstract][Full Text] [Related]
20. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus.
Kramer HJ; Nguyen QD; Curhan G; Hsu CY
JAMA; 2003 Jun; 289(24):3273-7. PubMed ID: 12824208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
